Can the AHCL System Be Used in T1D Patients with Borderline TDDI? A Case Report
| العنوان: | Can the AHCL System Be Used in T1D Patients with Borderline TDDI? A Case Report |
|---|---|
| المؤلفون: | Sebastian Seget, Przemysława Jarosz-Chobot, Anna Tekielak, Ewa Rusak |
| المصدر: | Sensors (Basel, Switzerland) Sensors, Vol 21, Iss 7195, p 7195 (2021) |
| بيانات النشر: | MDPI AG, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Pediatrics, medicine.medical_specialty, borderline total daily dose of insulin, medicine.medical_treatment, Case Report, TP1-1185, Biochemistry, Analytical Chemistry, remission, Remission phase, medicine, In patient, Electrical and Electronic Engineering, Instrumentation, Glycemic, Type 1 diabetes, business.industry, Chemical technology, Insulin, Diabetology, medicine.disease, advanced hybrid closed loop systems, Atomic and Molecular Physics, and Optics, Total Daily Dose, business, Closed loop, type 1 diabetes mellitus |
| الوصف: | (1) Background: Intensive insulin therapy using continuous subcutaneous insulin infusion (CSII) with continuous real-time glucose monitoring (rt CGM) is the best option for patients with T1D. The recent introduction of a technology called Advanced Hybrid Closed Loop (AHCL) represents a new era in the treatment of type 1 diabetes, the next step towards better care, as well as improving the effectiveness and safety of therapy. The aim is to present the case of a T1D patient with a borderline total daily dose of insulin being treated with the Medtronic AHCL system in automatic mode. (2) Materials and Methods: A 9-year-old boy, from October 2020, with type 1 diabetes in remission was connected to the Minimed™ 780G (AHCL) system in accordance with the manufacturer’s recommendations (daily insulin dose > 8 units, age > 7). Records of the patient’s history were collected from visits to The Department of Children’s Diabetology, as well as from the Medtronic CareLink™ software and the DPV SWEET program from October 2020 to April 2021. (3) Results: The patient’s total daily insulin requirement decreased in the first 6 weeks after the AHCL was connected, which may reflect the remission phase (tight glycemic control with a healthy lifestyle). The lowest daily insulin requirement of 5.7 units was also recorded. In a three-month follow-up of the patient treated with AHCL, it was found that for almost 38% of the days the insulin dose was less than 8 IU. (4) Conclusions: The AHCL system allows safe and effective insulin therapy in automatic mode, as well as in patients with a lower daily insulin requirement. The AHCL system should be considered a good therapeutic option for patients from the onset of T1D, as well in the remission phase. |
| تدمد: | 1424-8220 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7dfc867aef8a8715a9a631bd2f2bb3d7Test https://doi.org/10.3390/s21217195Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....7dfc867aef8a8715a9a631bd2f2bb3d7 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14248220 |
|---|